InflaRx N.V.

Analysis for Ticker: IFRX

InflaRx NV is a biotechnology company in Jena, Germany, that claims to develop medicine for severe inflammatory diseases by targeting specific proteins in the blood. The reality is that the company operates as a wealth transfer mechanism where capital is consumed to sustain a corporate structure that produces almost nothing. In 2025, the business generated exactly 29.331€ in revenue. To make that tiny amount of money, it spent 45,6€ million. This is like a business that spends forty-five thousand dollars on wood and nails to build a birdhouse but only sells it for twenty-nine dollars. The math is a disaster because the company loses money nearly two thousand times faster than it brings it in, resulting in an accumulated deficit of 377,8€ million.